Vinay Prasad

Associate Professor

  • 2690 Citations
  • 26 h-Index
20092019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2009 2019

Filter
Article
2019

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals

Herrera-Perez, D., Haslam, A., Crain, T., Gill, J., Livingston, C., Kaestner, V., Hayes, M., Morgan, D., Cifu, A. S. & Prasad, V., Jun 11 2019, In : eLife. 8

Research output: Contribution to journalArticle

Open Access
New England
American Medical Association
Medicine
Cardiovascular Diseases
Randomized Controlled Trials
1 Citation (Scopus)
Drug Approval
Quality Control
Randomized Controlled Trials
Standard of Care
Antineoplastic Agents
2 Citations (Scopus)
United States Food and Drug Administration
Biomarkers
Drug Approval
Pharmaceutical Preparations
Neoplasms
Open Access
Outcome Assessment (Health Care)
Neoplasms
Research Personnel
Cross-Sectional Studies
Clinical Trials
Conflict of Interest
Glioblastoma
Neoplasms
Equipment and Supplies
Registries

Confirmatory Trials for Drugs Approved on a Single Trial

Haslam, A. & Prasad, V., Jun 1 2019, In : Circulation. Cardiovascular quality and outcomes. 12, 6, p. e005494

Research output: Contribution to journalArticle

Valsartan
Drug Approval
Fish Oils
Pharmaceutical Preparations
1 Citation (Scopus)

Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

Chen, E. Y., Joshi, S. K., Tran, A. & Prasad, V., Jan 1 2019, In : JAMA Internal Medicine.

Research output: Contribution to journalArticle

Biomarkers
Clinical Trials
United States Food and Drug Administration
Drug Approval
Survival
9 Citations (Scopus)
Open Access
Immunotherapy
Pharmaceutical Preparations
Neoplasms
United States Food and Drug Administration
Melanoma

Improving the design of pivotal clinical trials

Prasad, V., Mar 1 2019, In : Clinical Advances in Hematology and Oncology. 17, 3, p. 150-152 3 p.

Research output: Contribution to journalArticle

Clinical Trials
3 Citations (Scopus)

Metastasis-free survival in prostate cancer: Faster drug approvals, better drugs?

Parikh, R. B. & Prasad, V., Feb 1 2019, In : Journal of Clinical Oncology. 37, 4, p. 266-268 3 p.

Research output: Contribution to journalArticle

Drug Approval
Prostatic Neoplasms
Neoplasm Metastasis
Pharmaceutical Preparations

Should Evidence Come with an Expiration Date?

Greene, P., Prasad, V. & Cifu, A., Jan 1 2019, In : Journal of general internal medicine.

Research output: Contribution to journalArticle

Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs

Haslam, A., Crain, T., Gill, J., Herrera-Perez, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : American Journal of Medicine.

Research output: Contribution to journalArticle

Newspapers
Health Care Costs
PubMed
Delivery of Health Care
Publications
2018
1 Citation (Scopus)

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply

Hernandez, I., Prasad, V. & Gellad, W. F., Jan 1 2018, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

T-Cell Antigen Receptor
Immunotherapy
Costs and Cost Analysis
5 Citations (Scopus)

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature

Nishikawa, G., Luo, J. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 143-151 9 p.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Neoplasms
History
Drug Therapy
Conflict of Interest

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Prasad, V., McCabe, C. & Mailankody, S., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Costs and Cost Analysis
1 Citation (Scopus)

A pooled analysis of published, basket trials in cancer medicine

Hazim, A. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 244-250 7 p.

Research output: Contribution to journalArticle

Medicine
Neoplasms
Fallopian Tube Neoplasms
Thymus Neoplasms
Seminoma
Cardiovascular Agents
Drug Therapy
Pharmaceutical Preparations
LCZ 696
3 Citations (Scopus)
Stroke
Myocardial Infarction
Clinical Trials
Neoplasm Metastasis
Recurrence
LCZ 696

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Hilal, T. & Prasad, V., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Biomarkers
Pharmaceutical Preparations
29 Citations (Scopus)

Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology

Marquart, J., Chen, E. Y. & Prasad, V., Aug 1 2018, In : JAMA oncology. 4, 8, p. 1093-1098 6 p.

Research output: Contribution to journalArticle

Genome
Neoplasms
United States Food and Drug Administration
Therapeutics
Pharmaceutical Preparations
4 Citations (Scopus)

Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings

Hayes, M. J. & Prasad, V., Mar 1 2018, In : Hastings Center Report. 48, 2, p. 10-13 4 p.

Research output: Contribution to journalArticle

Pharmacy and Therapeutics Committee
Conflict of Interest
conflict of interest
Advisory Committees
drug
6 Citations (Scopus)

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: Retrospective observational study

Wagner, J., Marquart, J., Ruby, J., Lammers, A., Mailankody, S., Kaestner, V. & Prasad, V., Jan 1 2018, In : BMJ (Online). 360, k668.

Research output: Contribution to journalArticle

United States Food and Drug Administration
Observational Studies
Retrospective Studies
Guidelines
Pharmaceutical Preparations
Simvastatin
Ezetimibe
2 Citations (Scopus)

Low-value approvals and high prices might incentivize ineffective drug development

Prasad, V., McCabe, C. & Mailankody, S., May 14 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology. p. 1-2 2 p.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Motivation
Clinical Trials
Neoplasms

Moving Precision Oncology Forward Amid Myths and Misconceptions - Reply

Marquart, J., Chen, E. Y. & Prasad, V., Jan 1 2018, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

PFO closure for secondary stroke prevention: is the discussion closed?

Shatzel, J. J., Daughety, M. M., Prasad, V. & Deloughery, T., Feb 20 2018, (Accepted/In press) In : Journal of Thrombosis and Thrombolysis. p. 1-3 3 p.

Research output: Contribution to journalArticle

Secondary Prevention
Stroke
1 Citation (Scopus)

The Necessity of Sham Controls

Prasad, V. & Cifu, A. S., Jan 1 2018, (Accepted/In press) In : American Journal of Medicine.

Research output: Contribution to journalArticle

The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another

Tao, D., Schott, S. & Prasad, V., Jan 1 2018, (Accepted/In press) In : American Journal of Medicine.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Neoplasms

The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint: Did it pay off?

Luo, J. & Prasad, V., Jun 1 2018, In : Journal of Cancer Policy. 16, p. 49-51 3 p.

Research output: Contribution to journalArticle

United States Food and Drug Administration
Pharmaceutical Preparations
Survival
pertuzumab
Disease-Free Survival

Why is research in early-stage cancer research so low?

Prasad, V. & Lindner, S., Sep 1 2018, In : Journal of Cancer Policy. 17, p. 4-8 5 p.

Research output: Contribution to journalArticle

Research
Pharmaceutical Preparations
Motivation
Neoplasms
2017
4 Citations (Scopus)

Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote

De Jesus-Morales, K. & Prasad, V., May 1 2017, In : Hastings Center Report. 47, 3, p. 9-14 6 p.

Research output: Contribution to journalArticle

Conflict of Interest
conflict of interest
corruption
Public Sector
Medicine
1 Citation (Scopus)
Pharmacy and Therapeutics Committee
Conflict of Interest
Drug Industry
Advisory Committees
United States Food and Drug Administration
20 Citations (Scopus)

Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable

Prasad, V. & Kaestner, V., 2017, (Accepted/In press) In : Seminars in Oncology.

Research output: Contribution to journalArticle

Cell Death
Monoclonal Antibodies
United States Food and Drug Administration
Head and Neck Neoplasms
CD274 Antigen
2 Citations (Scopus)

Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?

Prasad, V., Oct 4 2017, (Accepted/In press) In : Journal of General Internal Medicine. p. 1-3 3 p.

Research output: Contribution to journalArticle

Medicine
71 Citations (Scopus)

Research and development spending to bring a single cancer drug to market and revenues after approval

Prasad, V. & Mailankody, S., Nov 1 2017, In : JAMA Internal Medicine. 177, 11, p. 1569-1575 7 p.

Research output: Contribution to journalArticle

Research
Pharmaceutical Preparations
Neoplasms
Costs and Cost Analysis
United States Food and Drug Administration
1 Citation (Scopus)

Reversal of warfarin era thinking

Shatzel, J. J., Daughety, M. M., Prasad, V. & Deloughery, T., 2017, (Accepted/In press) In : Journal of Internal Medicine.

Research output: Contribution to journalArticle

Warfarin
41 Citations (Scopus)
Biomarkers
Pharmaceutical Preparations
Marketing
Uncertainty
Quality of Life
3 Citations (Scopus)

Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go

Beer, T. T. & Prasad, V., Jan 1 2017, In : JAMA oncology. 3, 1, p. 16-17 2 p.

Research output: Contribution to journalArticle

Attitude to Death
Terminal Care
Neoplasms
59 Citations (Scopus)

The high price of anticancer drugs: origins, implications, barriers, solutions

Prasad, V., Jesús, K. D. & Mailankody, S., Mar 14 2017, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Drug Costs
Pharmaceutical Preparations
Patient Harm
Patient Compliance
Health Expenditures
1 Citation (Scopus)

Use of word “unprecedented” in the media coverage of cancer drugs: Do “unprecedented” drugs live up to the hype?

Tayapongsak Duggan, K., De Jesus, K., Kemp, R. & Prasad, V., Dec 1 2017, In : Journal of Cancer Policy. 14, p. 16-20 5 p.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Neoplasms
Investigational Drugs
Literature
Drug Approval
5 Citations (Scopus)

What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature

Lu, E., Shatzel, J., Shin, F. & Prasad, V., Feb 1 2017, In : Seminars in Oncology. 44, 1, p. 8-12 5 p.

Research output: Contribution to journalArticle

Neoplasms
Incidence
Publications
Prostatic Neoplasms
Breast Neoplasms
2016

A conversation with Vinay Prasad, MD: To 'first, do no harm,' you must start with good evidence

Prasad, V., 2016, Managed Care, 2016, OCT.

Research output: Contribution to specialist publicationArticle

Early Detection of Cancer
Biomarkers
Oncologists
2 Citations (Scopus)

Application of Medicare's New Technology Add-on Payment Program for Blinatumomab

Dhruva, S. S. & Prasad, V., Feb 1 2016, In : JAMA oncology. 2, 2, p. 165-166 2 p.

Research output: Contribution to journalArticle

Drug Administration Schedule
Bispecific Antibodies
Health Insurance Reimbursement
Health Services Accessibility
Drug Costs

ASCO Plenary Sessions: Impact, legacy, future

Vandross, A., Prasad, V. & Mailankody, S., Jun 1 2016, In : Seminars in Oncology. 43, 3, p. 321-326 6 p.

Research output: Contribution to journalArticle

Industry
Active Immunotherapy
New England
Follicular Lymphoma
Glioblastoma
16 Citations (Scopus)

Assessing the eventual publication of clinical trial abstracts submitted to a large annual oncology meeting

Massey, P. R., Wang, R., Prasad, V., Bates, S. E. & Fojo, T., Feb 17 2016, In : Oncologist. 21, 3, p. 261-268 8 p.

Research output: Contribution to journalArticle

Publications
Clinical Trials
Odds Ratio
Sample Size
Industry

Balancing accelerated approval for drugs with accelerated withdrawal - In reply

Kim, C. & Prasad, V., Apr 1 2016, In : JAMA Internal Medicine. 176, 4, p. 567 1 p.

Research output: Contribution to journalArticle

Drug Approval
Antineoplastic Agents
4 Citations (Scopus)

Cardiovascular risk assessment in oncological clinical trials: Is there a role for centralized events adjudication?

Vaduganathan, M. & Prasad, V., Feb 1 2016, In : European Journal of Heart Failure. 18, 2, p. 128-132 5 p.

Research output: Contribution to journalArticle

Antineoplastic Agents
Comorbidity
Cardiovascular Diseases
Heart Failure
Clinical Trials
12 Citations (Scopus)
Pharmacy and Therapeutics Committee
Drug Approval
Conflict of Interest
Medicaid
Drug Industry
9 Citations (Scopus)

Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload

Boothby, A., Wang, R., Cetnar, J. & Prasad, V., Dec 1 2016, In : JAMA oncology. 2, 12, p. 1653-1654 2 p.

Research output: Contribution to journalArticle

Organizational Policy
Conflict of Interest
Medical Oncology
Medical Societies
Biomedical Research